1983-1987 - B.S., University of Texas Health Sciences Center at San Antonio
1994-1997 - MBA, Webster University, St. Louis, MO
Annette Fothergill is an Instructor in the Department of Pathology and the Technical Director of the Fungus Testing Laboratory (FTL). In addition to clinical reference work, the FTL is actively involved in research and clinical trials. Research activities are focused on testing of potential new compounds being considered for development by the pharmaceutical industry. The FTL also serves as the central laboratory in several clinical trials in cooperation with the pharmaceutical industry to assist with their submission of drugs to the FDA for approval. Additional interests are combination or synergy testing and evaluating new systems and equipment for fungal identification or susceptibility testing. Annette also serves as the point of contact for contracts between the FTL and sponsors.
A graduate of the University of Texas Health Science Center in Clinical Laboratory Sciences program, Annette began working in the Fungus Testing Laboratory in 1987. During her years in the FTL, Annette has actively involved in educating the medical community in the exciting field of medical mycology. Ms. Fothergill is on the review board of several peer reviewed journals, has served as workshop faculty both nationally and internationally, and has co-authored several journal articles, book chapters and scientific presentations in addition to the reference text "Guide to Clinically Significant Fungi".
Professional Society Memberships:
- American Society for Microbiology, Division F, Medical Mycology
- Texas Branch of the American Society for Microbiology
- International Society for Human and Animal Mycology
- Medical Mycological Society of the Americas
- South Texas Association of Microbiology Professionals
Description of Research
Our research involves the laboratory evaluation of antifungal agents and evaluation of new diagnostic tests. Activities include in vitro testing of both approved and investigational compounds against a wide-range of clinically significant fungi. Additionally, we participate in clinical trials and evaluate the efficacy of these agents both prior to FDA submission and following submission when seeking approval for expanded indications. The Fungus Testing Laboratory is an international reference laboratory receiving clinical specimens for antifungal susceptibility testing, antifungal drug level determination in serum or other sources and for identification. The laboratory is also appointed as a testing site for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.Unique Technical and Clinical Research Capabilities/Instrumentation:
The Fungus Testing Laboratory serves as an international reference laboratory for the identification of fungal isolates to the species level, provides in vitro susceptibility testing of both yeasts and moulds, including dimorphic pathogens, and determines antifungal drug levels in body fluids by bioassay, HPLC, and GLC methodologies. Additionally, we serve as a central laboratory for clinical trials of various approved/investigational antifungal agents.Publications
Koneman, E., D.A. Sutton, A.W. Fothergjll, M.G. Rinaldi, T. Sun, and S.F. Straus. 2001. LWW¹s Organism Central, Lippincott Williams & Wilkins, Hagerstown, MD.
Smith, LA, A.W. Fothergill, D.A. Sutton, J.L. Harris. 2000. Medically Significant Fungi. Chapter 23. In: Textbook of Diagnostic Microbiology, Second Edition, C. Mahon, G. Manuselis (ed.), Current Medicine.
Sutton, D.A., A.W. Fothergill, and M.G. Rinaldi. 1998. Guide to Clinically Significant Fungi. Williams & Wilkins, Baltimore, MD.
- A. Espinel-Ingroff, A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study. J. Clin. Microbiol. 2002 40: 3204-3208.
- Espinel-Ingroff A. Chaturvedi V. Fothergill A. Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J. Clin. Microbiol. 2002 40(10): 3776-81.
- Yildiran ST. Fothergill AW. Sutton DA. Rinaldi MG. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). [Journal Article] Mycoses. 2002 45(9-10):378-83.
- Redding SW. Kirkpatrick WR. Saville S. Coco BJ. White W. Fothergill A. Rinaldi M. Eng T. Patterson TF. Lopez-Ribot J. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. [Journal Article] J. Clin. Microbiol. 2003 41(2):619-2.
- Dahiya MC. Redding SW. Dahiya RS. Eng TY. Kirkpatrick WR. Coco BJ. Sadkowski LC. Fothergill AW. Waite A. Rinaldi MG. Patterson TF. Thomas CR. Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Intl. J. Rad. Onc., Bio., Physics. 2003. 57(1):79-83.
- Redding SW. Dahiya MC. Kirkpatrick WR. Coco BJ. Patterson TF. Fothergill AW. Rinaldi MG. Thomas CR Jr. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. [Journal Article] Oral Surg. Oral Med. Oral Path. Oral Radio. & Endodontics. 2004. 97(1):47-52.
- Francesco Barchiesi, Elisabetta Spreghini, Monia Maracci, Annette W. Fothergill, Isabella Baldassarri, Michael G. Rinaldi, and Giorgio Scalise. In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicr. Agents & Chemo. 2004. 48(9):3317-22.